Glenmark Pharmaceuticals Limited (Glenmark), An Innovation Driven, Global Pharmaceutical Company, Has Launched The First Triple Fixed-Dose Combination Teneligliptin With Pioglitazone And Metformin In India. Teneligliptin Is A Widely Used Dpp4 Inhibitor (Dipeptidyl Peptidase 4 Inhibitor). This Fdc Has Been Launched Under The Brand Name Zita-Piomet, And Contains Teneligliptin (20 Mg) + Pioglitazone (15 Mg) + Metformin (500Mg/1000Mg) In A Sustained Release (Sr) Formulation. This Offers Patients With Type 2 Diabetes The Convenience Of Once Daily Dosing To Improve Their Glycaemic Control And Achieve The Targeted Hba1C Within 24 Weeks. On Occasion Of The Launch, Alok Malik, Evp & Business Head - India Formulations, Glenmark Pharmaceuticals Ltd., Said,
